Literature DB >> 18428185

Isoquinolin-1-one inhibitors of the MDM2-p53 interaction.

Ulli Rothweiler1, Anna Czarna, Marcin Krajewski, Jolanta Ciombor, Cédric Kalinski, Vladimir Khazak, Günther Ross, Natalia Skobeleva, Lutz Weber, Tad A Holak.   

Abstract

p53 has been at the centre of attention for drug design since the discovery of its growth-suppressive and pro-apoptotic activity. Herein we report the design and characterisation of a new class of isoquinolinone inhibitors of the MDM2-p53 interaction. Our identification of druglike and selective inhibitors of this protein-protein interaction included a straightforward in silico compound-selection process, a recently reported NMR spectroscopic approach for studying the MDM2-p53 interaction, and selectivity screening assays using cells with the same genetic background. The selected inhibitors were all able to induce apoptosis and the expression of p53-related genes, but only the isoquinolin-1-one-based inhibitors stabilised p53. Our NMR experiments give a persuading explanation for these results, showing that isoquinolin-1-one derivates are able to dissociate the preformed MDM2-p53 complex in vitro, releasing a folded and soluble p53. The joint application of these methods provides a framework for the discovery of protein interaction inhibitors as a promising starting point for further drug design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18428185     DOI: 10.1002/cmdc.200800025

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  17 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

Review 2.  On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis.

Authors:  Cédric Kalinski; Michael Umkehrer; Lutz Weber; Jürgen Kolb; Christoph Burdack; Günther Ross
Journal:  Mol Divers       Date:  2010-03-16       Impact factor: 2.943

3.  trans-rac-[1-Oxo-2-phenethyl-3-(2-thien-yl)-1,2,3,4-tetra-hydro-isoquinolin-4-yl]methyl 4-methyl-benzene-sulfonate.

Authors:  Mehmet Akkurt; Sema Oztürk Yıldırım; Milen G Bogdanov; Meglena I Kandinska; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-17

4.  Stereoselective Synthesis of Quaternary Pyrrolidine-2,3-diones and β-Amino Acids.

Authors:  Nataliia V Shymanska; Joshua G Pierce
Journal:  Org Lett       Date:  2017-05-24       Impact factor: 6.005

5.  Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels.

Authors:  Daniela Schilling; Michael Düwel; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2012-08-30       Impact factor: 3.667

6.  Synthesis of DNA-coupled isoquinolones and pyrrolidines by solid phase ytterbium- and silver-mediated imine chemistry.

Authors:  Marco Potowski; Verena B K Kunig; Florian Losch; Andreas Brunschweiger
Journal:  Medchemcomm       Date:  2019-02-26       Impact factor: 3.597

Review 7.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

8.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

9.  Methyl trans-(±)-1-oxo-2-phenethyl-3-(thio-phen-2-yl)-1,2,3,4-tetra-hydro-isoquinoline-4-carboxyl-ate.

Authors:  Mehmet Akkurt; Selvi Karaca; Milen G Bogdanov; Meglena I Kandinska; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-05-14

10.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.